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THE increase in demand for infertility services in Westerncountries is probably due to different factors: 1) the
tendency of women to delay childbearing because of their
work so that desired reproduction is condensed into a shorter
interval than before and at a more advanced age (i.e. .30 or
even .35 yr), which by itself is a negative prognostic factor
for the woman’s fecundability; 2) an increase of effective
treatments by assisted reproductive techniques (ARTs); 3) an
increased awareness of such treatments. The prevalence of
infertile couples differs according to the definition of couple
infertility. If we accept the most commonly used definition,
i.e. the lack of pregnancy after 1 yr of unprotected regular
intercourse, infertile couples represent about 10–15% of all
couples. According to the definition of the European Society
for Human Reproduction and Embryology, i.e. the lack of
pregnancy within 2 yr by regular coital exposure, the prev-
alence of infertile couples in Europe and North America is
approximately 5–6% (1).
The causes of infertility can be divided into four major
categories: 1) the female factor; 2) the male factor; 3) com-
bined factors; 4) unexplained infertility. It is difficult to as-
sign exact percentage to each of these categories; however, it
is generally reported that in approximately 35% of cases,
infertility is mainly due to a female factor, in 30% to a male
factor, in 20% to abnormalities detected in both partners, and
in 15% of cases no diagnosis can be made after a complete
investigation (Table 1). In some couples there is no possibility
of natural conception because of sterility of the male
(azoospermia or lack of ejaculation) or of the female (ovarian
failure, tubal occlusion, absence of the uterus). Minor degrees
of fertility impairment are not necessarily associated with
couple infertility when present in only one partner but may
reduce the couple’s fertility when present in both partners.
The aim of the present review is to give the general en-
docrinologist a brief overview of a modern diagnostic and
therapeutic approach to the infertile couple.
Evaluation of the Infertile Couple
In the diagnostic approach, which should be clearly and
thoroughly explained to both partners, the sexual history of
the couple is very important. The frequency and timing of
intercourse and the use of lubricants should be assessed. It
happens frequently that an infertile couple abstains from
intercourse and has only ‘timed’ exposures in the middle of
the cycle, but there is no evidence that prolonged abstinence
increases the chances of pregnancy: abstinence (7–8 days)
should be reasonably recommended only if oligozoospermia
is present (2). Use of lubricants should be discouraged be-
cause of their detrimental effect on semen quality.
After the sexual history is obtained, a detailed medical
history and physical examination, followed by appropriate
diagnostic tests, should be performed in both partners in a
sequential way, as shown in Fig. 1.
Female Partner
Medical history and physical examination
Medical history. Ovulatory dysfunction can be suggested by
late menarch, presence of premenstrual syndrome, abnormal
cycle length, amount of menstrual loss, premenstrual spot-
ting, hot flushes (hypoestrogenism), and excessive physical
exercise and/or weight changes (due to eating disorders)
greater than 10% in the past year. Systemic diseases such as
diabetes mellitus and thyroid dysfunction that are not ade-
quately treated may also have adverse effects on fertility.
Medical treatments may cause temporary (sex steroids) or
permanent (cytotoxic agents, abdominal irradiation) damage
to the ovulatory function. Neuroleptic, antidepressant, and
hypotensive drugs and drugs for gastrointestinal symptoms
can cause hyperprolactinemia. The use of recreational drugs
such as marijuana and cocaine should also be investigated.
Spontaneous galactorrhoea must be ascertained and further
investigated for suspected hyperprolactinemia. The possible
negative effect of environmental and occupational factors in
relation to female fertility is under study. Although sub-
stances used in shoe, rubber, and textile manufacture have
been reported to interfere with menstrual cycle, further con-
trolled, prospective, and clinically detailed research is re-
quired (3).
The presence of a vaginal/cervical factor can be suspected
by a history of recurrent vaginal infections.
Excessive menstrual losses and dysmenorrhea may sug-
gest not only ovarian dysfunction but also the presence of a
uterine fibromyoma.
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Tubal obstruction can be suspected in women using in-
trauterine devices for contraception who have an increased
risk of pelvic inflammatory disease (PID) and therefore of
tubal disease. As the number of sexual partners increases the
incidence of sexually transmitted diseases, it is also an im-
portant associative risk factor for the development of sub-
sequent tubal infertility. Therefore, oral contraceptive users
are also at risk of such pathology. Infections by Chlamydia
trachomatis (4–6 times more frequent than by Neisseria gon-
orrhoeae in Western countries) are the most common causes
of infection-related tubal pathology. Previous abdominal
surgery, “complicated” appendicectomy, and gynecological
operations (ovarian cystectomy, edge resection of the ova-
ries) all predispose to adhesion formation and increase the
likelihood of tubal dysfunction. A history of tuberculosis can
be associated with a diagnosis of tubal damage. Severe dys-
menorrhea and deep dyspareunia may be related to endo-
metriosis or PID.
In secondary infertility (i.e. the woman has previously
been pregnant), details of previous pregnancies, including
TABLE 1. Approximate percentage distribution of diagnosis in infertile couples (modified from Ref. 1, Table 2)
Both partners Only female Only male
Sterile (%) 0.3 10 6
Subfertile (%) 20 25 24
Unexplained (%) 15
Definition Female partner Male partner
Sterile Bilateral tubal occlusion Aspermia/azoospermia
Amenorrhea with elevated FSH




Unexplained Normal endocrine profile Normal semen quality
Tubal patency Normal sexual function
FIG. 1. Flowchart of diagnostic assessment and therapeutic options in couple infertility. PCT, Post-coital test; COH, Controlled ovarian
hyperstimulation; IUI, intrauterine insemination; IVF, in vitro Fertilization; ICSI, intracytoplasmic sperm injection; TESA, testicular sperm
aspiration; TESE, testicular sperm extraction; PESA, percutaneous epididymal sperm aspiration; MESA, microsurgical epididymal sperm
aspiration.
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abortions, miscarriages, and ectopic and molar pregnancies,
must be recorded.
Physical examination. Physical examination should consider:
1) body shape and stature (short stature with webbed neck
suggest Turner’s syndrome); 2) calculation of the body mass
index (BMI 5 ratio between weight in kilograms and height
in square meters); 3) evaluation of secondary sexual char-
acteristics (hair distribution, breast development, spontane-
ous and manually induced galactorrhea, inspection of ex-
ternal genitalia); 4) abnormalities such as fibromyomata,
ovarian cysts, or fixed retroversion of the uterus can be
diagnosed with a bimanual examination of the uterus asso-
ciated with the palpation of the fornices. The vagina and the
cervix must be examined, and any discharge should be fur-
ther investigated for infection; 5) the cardiovascular, respi-
ratory, and gastrointestinal systems must be carefully exam-
ined before pregnancy is planned.
First-Level Diagnostic Tests
Hormonal assessment of ovulatory function
Anovulatory infertility can be associated with oligo/am-
enorrhea but also with apparently normal menstrual cycles.
Unfortunately, there is no established method to ascertain
the completion of a normal ovulatory cycle in a woman. The
most cost-effective compromise seems to be the measure-
ment of midluteal progesterone concentrations in plasma (at
least two assays) which must be .18 nmol/L (.5.6 ng/mL)
and the measurement of basal body temperature for at least
2–3 months (3). In secondary amenorrhea or oligomenorrhea
measurement of circulating estradiol or gestagen challenge,
measurement of FSH, LH, and PRL (in the early follicular
phase, if menses are present) are necessary. When hirsutism
and/or acne is present, circulating androgens (testosterone,
androstenedione, dehydroepiandrosterone sulfate) and 17-
hydroxy-progesterone must be measured. According to the
results, if 21-hydroxylase deficiency (usually the late-onset
form) is suspected, an ACTH challenge test and/or a dexa-
methasone suppression test can be indicated. Polycystic
ovary syndrome (PCOS) is likely in patients with BMI . 25,
hirsutism, a LH/FSH ratio . 2, and high androgen levels.
Transvaginal ultrasound scanning of the ovaries can be use-
ful even if there is no general agreement about the ultrasound
features of PCOS (4, 5).
In hyperprolactinemia, use of dopamine receptor-blocking
agents or central nervous system dopamine-depleting agents
must be excluded. TSH should then be measured to exclude
primary hypothyroidism. Pituitary imaging with computer-
ized tomography or nuclear magnetic resonance will confirm
or exclude sellar (micro- or macroadenoma) or suprasellar
organic pathology.
Although luteal phase defect has been clearly described by
several authors, the currently available diagnostic tests (en-
dometrial biopsy dating, daily progesterone measurements)
are cumbersome and not properly validated.
Premature ovarian failure is suspected in women younger
than 40 yr with high FSH levels (.40 IU/L) obtained at least
1 month apart and low estrogen levels. While karyotype is
part of the assessment, the necessity of ovarian ultrasound,
measurement of ovarian antibodies, and ovarian biopsy is
open to question. In the case of suspected autoimmune
polyglandular syndrome, screening for other endocrine ab-
normalities is mandatory.
Tubal patency assessment
Evaluation of tubal patency can be considered a first-level
diagnostic test in a normal cycling woman with a normo-
zoospermic partner and a history of dysmenorrhea and/or
dyspareunia, previous PID, or abdominal surgery. In order
to assess tubal patency, hysterosalpingography (HSG) is usu-
ally performed in the early follicular phase. Since both false
negative and false positive results have been reported, fur-
ther investigation of tubal patency may be obtained by the
more invasive and expensive laparoscopy. Retrograde tubal
cannulation under radiographic guidance during HSG or
laparoscopic inspection, completes the diagnosis of proximal
tubal occlusion. Laparoscopy, in contrast to HSG, allows the
identification of peritubal adhesions either of inflammatory
origin or due to endometriosis. A direct visualization of the
tubal lumen has been proposed by tubal catheterization via
laparoscopy, hysteroscopy, or more recently, transcervically
as an outpatient procedure (falloposcopy).
Second-Level Diagnostic Tests
If normal ovulatory function is ascertained, disturbance in
the passage of the oocyte and/or the spermatozoa must be
considered at different levels of the female genital tract.
Cervical factors. All forms of vaginitis may include cervicitis,
leading to a change in cervical mucus pH, which is detri-
mental to the motility and the ascent of sperm. If vaginal
discharge and/or low abdominal pain is present, a bacteri-
ological examination is necessary in order to exclude infec-
tion by common Gram-positive and Gram-negative bacteria,
Chlamydia trachomatis, Neisseria gonorrheae, Ureaplasma urea-
lyticum, and Mycoplasma hominis. In patients affected by re-
current cervicitis, colposcopy is recommended to rule out
cervical metaplasia/dysplasia.
Abnormal sperm-cervical mucus interaction. The most com-
monly used technique for identifying this abnormality is the
postcoital test (PCT). Before PCT is performed, vaginal in-
fections must be excluded and optimal timing carefully as-
sessed. A negative (abnormal) result of PCT is accepted as
valid only if the mucus is of acceptable quantity and quality
(score . 10) (6). The predictive values of normal and abnor-
mal PCT results are rather poor, although a cut-off point of
normality at the point of at least one motile spermatozoon
per high power (3400) field may be a worthwhile option (7).
If a pathological PCT result is found despite favorable cer-
vical mucus score, the cervical secretion should be tested for
qualitative and quantitative sperm antibody determination.
The significance of female circulating antibodies has yet to be
determined.
Uterus abnormalities. The diagnosis of infertility secondary to
uterine abnormalities is one of exclusion. With the exception
of uterine hypoplasia/agenesis, the relationship between
congenital or acquired uterine defects (leiomyomata, intra-
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uterine adhesions) with an impaired ability to conceive is
open to question. On the other hand, uterine anomalies cer-
tainly play an important role in recurrent pregnancy losses
(12–15%). The integrity of the uterus is usually assessed by
pelvic and transvaginal ultrasound. Further information can
be obtained by HSG and/or hysteroscopy.
Tubal factors. Congenital anomalies are less important than
acquired conditions, such as adhesions caused by endome-
triosis and infections. Since many pelvic infections (especial-
ly Chlamydia infection) have no or only nonspecific symp-
toms, tubal patency should be assessed in all women with
normal ovulation and normal PCT who do not achieve preg-
nancy within 6–12 months.
The assessment of tubal patency is not necessary in couples
affected by severe male factor in whom in vitro fertilization
(IVF) or intracytoplasmic sperm injection (ICSI) and embryo
transfer (ET) are the only possible therapeutic options (see
Table 2).
Genetic assessment
Karyotyping is indicated in women with primary or sec-
ondary amenorrhea with elevated serum FSH, in long-term
unexplained infertility, and in recurrent spontaneous
abortion.
Recurrent early abortions/previous repeated failures
of ARTs
Autoantibodies against phospholipids such as anticardio-
lipin have been reported to reduce implantation and preg-
nancy rates after IVF and to be associated with recurrent
early abortions. As the incidence of autoantibodies against
phospholipids is much higher in infertile (range, 15–45%)
than in fertile women (range, 1–4%), their measurement is
advisable in women with previous failure of ARTs. How-
ever, standardization of methods of detection, quality con-
trol, and careful interpretation of positive results is required (8).
Treatment of the Infertile Female
Anovulatory infertility. There is a large variety of conditions
between persistent anovulation and normal ovulation. Ir-
regular ovulation can be a cofactor, whereas chronic anovu-
lation is obviously a definite cause of infertility. Changes in
life-style can be simple, but necessary, measures in cases of
obesity, malnutrition, overexercise, and drug use. Specific
treatments apply if anovulation is due to hormonal abnor-
malities. The four most frequent conditions are normogona-
dotropic, hypergonadotropic, hyperprolactinemic, and hy-
pogonadotropic anovulation.
Normogonadotropic anovulation. These women (usually with
PCOS) have normal FSH levels but LH may be elevated. In
overweight patients (BMI . 25) the treatment of choice is an
antiestrogen such as clomiphene citrate or tamoxifen com-
bined, when possible, with weight reduction. There is no
documented advantage for sequentially combining clo-
mifene with human (h) CG or estrogen. Recently, the insulin-
sensitizing agent troglitazone has been reported to improve
ovarian function in women with PCOS and therefore pro-
posed as a novel therapy (9). In women unresponsive to
clomiphene (;50%), laparoscopic ovarian electrocautery can
be proposed: although the cumulative pregnancy rate re-
ported after this type of treatment has been reported to be
around 50%, ensuing risks of postoperative adhesions must
be considered (10). A most commonly used alternative ther-
apy is the administration of pulsatile GnRH or human pu-
rified or recombinant FSH to induce multiple follicular
growth followed by hCG and timed intercourse or an ART.
TABLE 2. Definitions of the most used assisted reproductive techniques
Intrauterine insemination (IUI): Spermatozoa previously selected are placed in the uterine cavity
using a catheter after ovulation. IUI represents the first step
in the treatment of young couples with no evidence of tubal
damage or severe male factor.
In vitro fertilization (IVF) and embryo transfer (ET) After controlled ovarian stimulation, follicular aspiration is
performed under transvaginal ultrasound guidance, and the
oocytes are incubated for 3–6 hr and then inseminated with
sperm in vitro. Two days after oocyte recovery, fertilized
oocytes should have cleaved to embryos containing two to
eight cells. After grading, two to three embryos are
transferred in the uterus. IVF was started to treat infertility
due to tubal impairment, but is largely used in many other
forms of infertility.
Gamete intrafallopian transfer (GIFT) This technique is an alternative to IVF-ET in women with
normal fallopian tubes and involves the direct placement of
sperm and oocytes into the ampullary portion of the tube,
allowing IVF to occur at the natural site. A laparoscopic
procedure under general anesthesia is usually needed.
Zygote intrafallopian transfer (ZIFT) The technique involves IVF and transfer of the zygotes to the
fallopian tube.
Intracytoplasmic sperm injection (ICSI) Direct injection of a single sperm into the cytoplasm of an
oocyte. This technique is indicated in severe male factor. It is
also used in azoospermic patients after retrieval of
spermatozoa from the epididymis by microsurgical sperm
aspiration (MESA) or from the testis by testicular sperm
aspiration (TESA) from a needle biopsy or by testicular sperm
extraction (TESE) from an open biopsy.
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Instead of traditional high-dose step-up regimen (which rep-
resents a higher risk of ovarian hyperstimulation syndrome),
new schedules have been suggested in order to recruit as few
follicles as possible and to allow selection and dominance to
occur (11).
Hypergonadotropic anovulation (premature ovarian failure). In
women with persistently high FSH levels (.40 IU/L), no
treatment has been prospectively proven to restore ovula-
tion; however, spontaneous, transient remission can occur.
Adoption or ovum donation could be an option for these
couples. In an early phase of premature ovarian failure, when
the woman is still cycling and FSH levels are rather high, but
not in the menopausal range (i.e. 15–25 IU/L), a controlled
ovarian hyperstimulation can be proposed both for an IVF
attempt (although with a poor success rate) and/or in order
to cryopreserve the oocytes for later ARTs in appropriate
laboratories. (Cryopreservation of oocytes, however, has not
yet obtained good results.) A follow up for subsequent au-
toimmune polyglandular syndrome or non-organ-specific
autoimmunity is recommended.
Hyperprolactinemic anovulation. The treatment of first choice
for pituitary hyperprolactinemia (either functional or due to
micro- or macroprolactinoma) is bromocriptine. Transphe-
noidal surgery can be an alternative option for micropro-
lactinomas or can be necessary if shrinking of a macroad-
enoma does not occur (12). Chemically releated dopamine
agonists such as pergolide and cabergoline may be suggested
in cases of intolerance to bromocriptine. If cycling does not
return despite normalized PRL concentrations, the pituitary-
thyroid and pituitary-adrenal axis function should also be
checked. If pituitary function is normal, dopamine agonists
can be combined with antiestrogens to induce ovulation.
Hypogonadotropic anovulation. Underweight patients (BMI ,
19) who are malnourished and/or who have exercised ex-
cessively must be counseled and must resume weight before
pharmacological treatments. If primary pituitary failure is
present, ovulation may be induced with gonadotropins. If
the pituitary failure is secondary to hypothalamic dysfunc-
tion, pulsatile GnRH therapy is the most appropriate.
At this time no association has been demonstrated be-
tween infertility and luteal phase defect detected by histo-
logical or hormonal evaluation. In any case, in women with
suspected luteal insufficiency progesterone supplementation
may be attempted during the luteal phase for three to six
cycles.
Tubal infertility. If semen analysis is normal, surgical tubal
reconstruction (ovariosalpingolysis, salpingoneostomy, fim-
brioplasty) can be considered before IVF is attempted. Since
the success of surgery depends on the tubal mucosal ap-
pearance, in the case of damaged mucosa or impaired semen
parameters, IVF-ET is the first treatment choice. On the basis
of hormonal characteristics of the woman, several ovarian
stimulation protocols are available for IVF.
Endometriosis. Women with minimal to mild endometriosis
represent the majority of endometriosis-associated infertil-
ity. These women are usually treated with ovarian suppres-
sion either with GnRH agonists or with danazole, medroxy-
progesterone acetate, oral contraceptives, and gestrinone.
Some randomized clinical trials have compared ovulation
suppression vs. placebo therapy and have shown no evi-
dence of a treatment effect. The aggregate pregnancy rates
reported after withdrawal of treatment were 41% in women
with placebo therapy and 41%, 40%, 36%, 35%, and 28% in
women treated with medroxyprogesterone acetate, oral con-
traceptive, GnRH agonist, danazole, and gestrinone, respec-
tively (1). Severe endometriosis associated with tubal ob-
struction, ovarian endometriomas, extensive adhesions, and
cul-de-sac obliteration are indications for surgical treatment.
Compared with ovulation suppression or no therapy, sur-
gical treatment has a significant effect; however, further con-
trolled trials are needed for final conclusions (1).
Vaginal and cervical factors. Infection or inflammation of va-
gina and/or cervix could necessitate medical therapy. In the
case of cervical metaplasia/dysplasia, electroresection or la-
ser surgery is recommended. In patients with a negative
(abnormal) PCT and the presence of antisperm antibodies,
intrauterine insemination (IUI) is recommended.
Uterus abnormalities. Intrauterine septa or submucosal fi-
broids should preferably be treated by hysteroscopic elec-
troresection. Excision of intramural or subserosal myomas
must be done by macrosurgery.
Recurrent early abortion. If antiphospholipid antibodies are
present, heparin and aspirin treatment is the therapy of
choice. However, in patients treated by aspirin/heparin and
undergoing IVF, the higher implantation and pregnancy
rates reported by several authors were obtained in noncon-
trolled studies. Therefore, prospective, randomized clinical
trials are needed to evaluate the role of antiphospholipid
antibodies in female infertility and the effects of heparin and
aspirin therapy on IVF outcome (8).
General cautions for ovulation induction
Before any ovulation induction, a pelvic ultrasound ex-
amination is necessary in order to exclude an ovarian mass
and/or uterine abnormalities. In the case of clomiphene
treatment the woman should be monitored monthly by ul-
trasound in order to control persistent ovarian follicular en-
largement. There is no need to monitor follicle growth during
treatment with antiestrogen and the pulsatile administration
of GnRH. Ovarian stimulation with human gonadotropins
[human menopausal gonadotropin (hMG)/FSH 1 hCG] is
usually performed in patients undergoing ARTs and can be
required also in patients with ovulatory disorders unrespon-
sive to other therapies. Since ovarian hyperstimulation syn-
drome is a recognized complication of such treatment, a
careful ultrasound monitoring every 2 days and/or plasma
estradiol measurement are mandatory. However, the num-
ber of preovulatory follicles and the estradiol concentrations
suggesting the risk of ovarian hyperstimulation at the time
of hCG injection are different from center to center (11).
Ovulation induction and ovarian cancer risk
Available data in the literature do not resolve the question
concerning a causal relationship between fertility drugs and
CLINICAL REVIEW 4181
 at Univ Studi Firenze Fac Di Medicina Bibl on July 22, 2008 jcem.endojournals.orgDownloaded from 
ovarian cancer. It seems to be that infertility alone is an
independent risk factor. Large prospective studies with care-
fully selected control groups are needed. Until such data are
forthcoming, close clinical surveillance of patients with ul-
trasound or other imaging techniques before, during, and
after treatment of infertility is warranted (13).
Male Partner
Medical history and physical examination
Testicular dysfunction. Testicular dysfunction due to acquired
gonadotropin defect is associated with few symptoms such
as the reduction of the volume of the ejaculate, reduction of
beard growth and libido, and asthenia. On the other hand,
a eunuchoid habitus with infantile genitalia, sparse or nearly
absent body hair, gynecomastia, and low testicular volume
(5–10 mL) is typical of congenital gonadotropin deficiency,
which can be associated with hypo- or anosmia in Kall-
mann’s syndrome. The assessment of testicular volume by
scrotal palpation and comparison with ellipsoids of known
volume (Prader’s orchidometer) is very important in the
infertile male, as the seminiferous tubules represent approx-
imately 80–85% of the testicular mass. Therefore, a small
testicular volume (,15 mL) suggests a significant impair-
ment of the seminiferous tubules.
Nonendocrine testicular dysfunction. Nonendocrine testicular
dysfunction can be suspected in men with varicocele or a
history of excess alcohol consumption, drug abuse, human
immunodeficiency virus infection, occupational exposure to
toxicants (lead, arsenic), ongoing medical treatments (ana-
bolic steroids, cancer chemotherapy, sulfasalazine, nitro-
furantoin), high fever in the past 6 months, testicular injury,
mumps orchitis, surgery for varicocele, and cryptorchidism.
Small testes (,15 mL) can be observed in these men. In men
with extremely small (,5 mL), firm testes, with or without
eunuchoid habitus and gynecomastia, Klinefelter’s syn-
drome is suspected.
Impairment of sperm transport and/or accessory gland infections.
Impairment of sperm transport and/or accessory gland in-
fections can be suggested by a history of sexually transmitted
disease, epididymitis, prostatitis, urinary infection, or ingui-
nal surgery. These men usually have a normal testicular
volume. Signs of epididymal inflammation such as thicken-
ing, nodules and/or pain can be also found at scrotal pal-
pation. Absence of the vas deferens can be also suggested, in
skilled hands, by scrotal palpation. Examination of the pros-
tate gland by digital rectal examination may be omitted if
there is no history, physical signs, or indication from urine
or semen analysis that the patient may have any disease of
the accessory sex glands.
The presence of penile abnormalities such as hypospadias,
surgical or traumatic penile scars, and induration plaques
should be assessed in every subject.
First-Level Diagnostic Tests
Semen analysis. In the investigation of a couple at least one
semen analysis is always mandatory and should be per-
formed according to the World Health Organization recom-
mended procedure (14). The manual provides normal values
(Table 3) as well as nomenclature for normal and patholog-
ical findings (Table 4). Normal values help to identify pa-
tients who should have no difficulty in inducing a preg-
nancy; however, unless there is a severe oligozoospermia or
azoospermia, the predictive value of subnormal semen vari-
ables is limited. The introduction of computer-assisted se-
men analysis, which requires expensive and sophisticated
equipment, has not yet led to any substantial improvement
in diagnosis and must be still considered mainly a research
tool (1).
If the first semen analysis is normal, there is generally no
need for a repeat analysis. In all other circumstances in which
an abnormal semen sample is obtained, an additional semen
sample should be examined after an interval of 6–12 weeks
(spermatogenesis takes ;3 months to be completed) because
of the large variability of semen parameters (14). In azoosper-
mia, after centrifugation of the semen sample, a careful anal-
ysis of the pellet is also necessary.
When azoospermia is present, obstruction should be dis-
tinguished from seminiferous tubular damage (see also Fig.
2B). A reduced bilateral testicular volume, (,10–12 mL),
with normal volume ejaculate (.2 mL) and high FSH is
indicative of damaged spermatogenesis. Obstructive




Sperm concentration .20 3 106 spermatozoa/mL
Total sperm count .40 3 106 spermatozoa/ejaculate
Motility .50% with forward progression (categories a and b) or .25% with rapid progression
(category a) within 60 min of ejaculation
Morphology .30% with normal forms
Vitality .75% or more live, i.e. excluding dye
White blood cells ,1 3 106/mL
Immunobead test ,20% spermatozoa with adherent particles
Mixed agglutination reaction test ,10% spermatozoa with adherent particles
Optional tests
a-Glucosidase (neutral) .20 mU per ejaculate
Zinc (total) .2.4 mmol per ejaculate
Citric acid (total) .52 mmol per ejaculate
Acid phosphatase (total) .200 U per ejaculate
Fructose (total) .13 mmol per ejaculate
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azoospermia is usually characterized by a normal testicular
volume and normal FSH levels. In these patients, very simple
semen parameters such as lack of coagulation, low volume
of the ejaculate, and acidic pH can suggest congenital bilat-
eral absence of vas deferens (CBAVD) and seminal vesicles,
a condition that is associated with a high incidence of mu-
tations in the cystic fibrosis gene. In CBAVD as well as in the
rare cases of acquired ejaculatory duct obstruction, seminal
fructose, which is produced by seminal vesicles, is usually
very low. Low levels of seminal a-glucosidase, the most
frequently used epididymal marker, are present in CBAVD,
in men with epididymal obstruction, but also in some men
with azoospermia due to tubular damage (15).
In astheno/oligoasthenozoospermic patients, immuno-
logical infertility and/or infection of sex accessory glands
may be suspected (see also Fig. 2A). If the percentage of
motile spermatozoa coated by antisperm antibodies is more
than 50%, a pure immunological factor is likely and titration
of sperm antibodies in serum will add weight and confirm
the diagnosis. If semen has high viscosity, pH . 8, and more
than 106 leukocytes/mL and/or reduced seminal levels of
prostatic markers (acidic phosphatase, citric acid, zinc), ac-
cessory gland infection (prostatitis or prostatovesiculitis) is
likely. The clinical significance of isolated leukocytospermia
as well as the role of subclinical genital infections in male
infertility is controversial (16).
FSH, LH, and testosterone measurement. The most important
hormonal measurement in the infertile male, both from the
diagnostic and prognostic point of view, is serum FSH (see
also Fig. 2, A and B). High FSH levels and normal LH and
testosterone levels are present in the majority of normally
virilized infertile men with sperm concentration lower
than 5 3 106/mL and are usually related to the entity of
spermatogenetic damage (17). Low levels of FSH, LH, and
testosterone suggest acquired hypogonadotropic hypo-
gonadism, which might be due to a prolactinoma or a non-
functioning pituitary tumor. Serum inhibin B levels have
been recently reported to be inversely related to FSH in
infertile men, suggesting that inhibin B levels reflect Sertoli
cell function (18). However, the diagnostic value of inhibin
B measurement in the routine assessment of male infertility
has still to be evaluated.
Using this approach (medical history and physical exam-
ination with testicular volume assessment, semen analysis,
and hormone measurement), a definite diagnosis of the cause
of male infertility can be obtained in approximately 70% of
cases (19). Further investigation may be warranted, based on
the initial findings and the therapeutic approach recom-
mended to the couple (see also Figs. 1 and 2, A and B).
Second-Level Diagnostic Tests
Bacteriological examination, transrectal, and scrotal ultrasound.
In men with asymptomatic leukocytospermia and a positive
bacteriological examination, some ultrasonographic criteria
have been considered indicative of chronic prostatitis (glan-
dular asymmetry, areas of calcification, dilation of the
periprostatic venous plexus) or vesiculitis (enlargement and
asymmetry, thickening and calcification of the glandular ep-
ithelium) (20). Due to its high cost, transrectal ultrasound is
a complementary diagnostic tool used mainly in countries
with socialized health care (European countries), whereas in
the United States, because it does not influence the antimi-
crobial treatment of the infection, it is a debatable option.
In a prospective study of 1048 consecutive patients at-
tending a fertility clinic, scrotal sonography showed abnor-
malities of the scrotal content in 50.4% of them. Most ab-
normalities were benign (varicocele, increased size of the
epididymis, epididymal cysts, hydrocele, testicular cysts);
however, the 1:200 incidence of testicular tumors in that
study was much higher compared with the 1:20.000 inci-
dence in the general male population (21). Therefore, testic-
ular ultrasonography can be suggested as a diagnostic tool
especially in patients with an increased risk of malignancy,
e.g. those with a previous history of cryptorchidism.
Genetic assessment. Chromosome abnormalities are much
more frequent in infertile males (5.3%) than in the general
population (0.6%) (22); therefore, karyotype must be per-
formed in men with azoospermia and severe oligozoosper-
mia if FSH levels are increased and testicular volume is
markedly reduced. The most frequent abnormalities are sex
chromosome aneuploidies such as the 47,XXY and the 47,
XYY karyotype (1:500 and 1:750 newborns, respectively),
autosomal Robertsonian translocations, and other types of
translocations. Of the various genes considered critical for
the regulation of male fertility, genes on the long arm of the
Y chromosome (Yq), especially within deletion interval 6,
also known as Yq 11.23, are the most promising. Most mac-
roscopic deletions in Yq11 are associated with impaired sper-
matogenesis, but microdeletions of three regions of the Y
chromosome were found recently in a large sample of oli-
gozoospermic and azoospermic men, and the regions were
named azoospermia factor AZFa, AZFb, and AZFc, respec-
tively; within the AZFc region a gene family termed DAZ
(deleted in azoospermia) has been identified. AZFb deletion
intervals include members of a related gene family (RBM, for
RNA binding motif) which, like DAZ, are predicted to en-
code testis-specific RNA binding proteins (23).
The frequency of microdeletions of these regions of the Y
TABLE 4. Nomenclature for normal and pathological findings in semen analysis according to WHO (1992)
Normozoospermia Normal ejaculate (as defined in Table 2)
Oligozoospermia Sperm concentration ,20 3 106/ml
Asthenozoospermia ,50% spermatozoa with forward progression (categories a and b) or ,25% spermatozoa with
category a movement
Teratozoospermia ,30% spermatozoa with normal morphology
Oligo-astheno-terato-zoospermia Signifies disturbance of all three variables (combination of only two prefixes may also be used)
Azoospermia No spermatozoa in the ejaculate
Aspermia No ejaculate
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chromosome reported by several authors in azoospermic and
severely oligozoospermic males ranges between 3 and 18%
(24). Men with deletions in peripheral blood lymphocytes
also have the deletions in ejaculated sperm.
In patients with CBAVD, which is now considered a mild
form of cystic fibrosis, screening for cystic fibrosis gene mu-
tations should be performed since mutations of this gene
have been reported in approximately 70–80% of such pa-
tients, the most frequent being the DF508 mutation (25). Due
to the high carrier frequency in Europe and North America
(1:25) genetic screening should also be done in the female
partner especially if an ART attempt (usually epididymal
sperm aspiration coupled to ICSI) is planned.
Third-level diagnostic tests
Testicular biopsy. Until recently testicular biopsy was a pro-
cedure designed to confirm a normal spermatogenesis in
patients with suspected obstructive azoospermia (with nor-
mal FSH and normal testicular volume) before reconstructive
microsurgery. Today, testicular biopsy can be considered
more a therapeutic than a diagnostic procedure. Testicular
sperm can be obtained from testicular biopsies of men with
azoospermia caused by obstruction, maturation arrest, or
Sertoli cell-only Syndrome and can be successfully used for
ICSI treatment (26). There is no general agreement concern-
ing the most successful way for testicular sperm retrieval.
Some authors found open testicular biopsy to be the best way
(27), but fine-needle testicular aspiration or testicular sperm
extraction, in expert hands, seems to be a most effective
alternative. Cryopreservation of a fraction of retrieved tes-
ticular spermatozoa is suggested for further ICSI cycles.
Sperm function tests. As routine semen analysis provides little
information on sperm-fertilizing ability and the percentage
of fertilization failure in ARTs is rather high in cases where
the male partner is subfertile, the possibility of predicting the
sperm-fertilizing ability would be of great help in choosing
the most appropriate ART. Several sperm function tests have
been reported to highly predictive of the sperm’s ability to
fertilize human oocytes in vitro (28). As shown in Table 5, the
best results are obtained with the hemizona assay, which
measures the ability of spermatozoa to bind to the zona
pellucida of a human oocyte, but the scarcity of human
oocytes makes this test unlikely to be used for routine pur-
poses. A good alternative option seems to be the sperm
responsiveness to progesterone. Progesterone is able to in-
duce, through a nongenomic mechanism, both intracellular
calcium increase and acrosome reaction in human sperma-
tozoa. We have recently reported, in a large group of un-
selected couples, that increases both in acrosome reaction
and intracellular free calcium concentration in response to
progesterone were good predictors of IVF rate (28).
Treatment of the Infertile Male
In contrast to infertile females, only a small percentage of
infertile or subfertile males can undergo a rationale, effective
treatment. Before considering specific treatments, however,
we must remember that expectant management can be an
option if the duration of infertility is less than 3 yr and the
woman’s age is less than 30 yr, because the fecundity of the
woman can often compensate for the presence of low sperm
concentration (even , 5 3 106/mL) and motility (,20%)
(29, 30).
Rationale treatment (medical or surgical)
In the few patients in whom infertility is due to hypogo-
nadism secondary to pituitary or hypothalamic failure, treat-
ment with hMG 1 hCG or pulsatile GnRH, respectively, is
highly effective in achieving sperm quality sufficient to in-
duce a pregnancy. If infection of the sex accessory glands is
present, appropriate treatment with antibiotics must be per-
formed in both partners. Disorders of ejaculation may be
treated in various ways, e.g. by electroejaculation or by re-
covery of spermatozoa from urine coupled to an ART. Ob-
structive azoospermia may be further investigated with va-
sography, and in some cases microsurgical reconstruction or
anastomosis can give good results. Better results, however,
are usually obtained with microsurgical epididymal sperm
aspiration and ICSI (see below). Concerning varicocele there
is still controversy about whether treatment improves male
fertility, and of the four published controlled, prospective
randomized trials recently reviewed, treatment improved
fertility in two and had no effect in the other two (31). How-
ever, there is some consensus that, in view of the apparent
progressive nature of this condition, intervention should be
suggested 1) in adolescents as a preventive measure if the
testicular volume of the affected size is reduced 3 mL or more
TABLE 5. Main characteristics of some sperm function tests: correlation (r value) with in vitro % fertilization rate of oocytes, sensitivity,
specificity, positive and negative predictive values (PPV and NPV)
Test Correlation with % fertilization rate (r value) Sensitivity (%) Specificity (%) PPV (%) NPV (%)
Morphology by strict criteria 0.31 94 40 22 98
Hemizona assay 0.75 100 94 85 100
AR induction by A23187 0.30 85 58 87 53
AR induction by follicular fluid 0.39 55 71 75 49
AR induction by progesterone 0.49 89 60 91 64
[Ca21]i induction by progesterone 0.44 96 53 89 77
AR, Acrosome reaction; [Ca21]i, intracellular free calcium concentration.
(Adapted from Ref. 28).
FIG. 2. Flowchart of diagnostic assessment and therapeutic options in the male partner of an infertile couple affected with (A) mild oligoas-
thenozoospermia or (B) azoospermia (or severe oligozoospermia). TV, Testicular volume; MAR test, mixed agglutination reaction test (see also
Table 2); T, testosterone; CT, computerized tomography; MRI, magnetic resonance imaging; CF, cystic fibrosis. *, See also flowchart for couple
infertility (Fig. 1): sperm function tests are required mainly for appropriate selection of an ART.
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compared with the contralateral testis, and 2) in young in-
fertile couples (both partners , 30 yr), with a duration of
infertility lower than 3 yr if the male partner has subnormal
semen analysis (31).
Empirical treatment
In patients with idiopathic semen abnormalities, different
kinds of empirical pharmacological treatments have been
tried: androgens, hMG/hCG, clomiphene, bromocriptine,
aromatase inhibitors, mesterolone, tamoxifene, kallicrein.
None of these treatments, however, has been demonstrated
to be effective in controlled, double-blind randomized stud-
ies (32).
ARTs
It is obvious that when few sperm are available, the
chances of sperm-egg interaction in vivo are reduced. To
overcome this difficulty, initial attempts have been made to
bring selected sperm closer to the oocyte by IUI. The clinical
effectiveness of IUI with sperm selected by appropriate tech-
niques in couples with male factor is not significantly dif-
ferent from no treatment; however if IUI is coupled to in-
duction of multiple ovulation, a significant increase of
pregnancy rates occurs (1). The results of IUI are also related
with the number and quality of inseminated sperm. Usually
a minimal number of selected motile sperm (1–2 3 106) is
required for an IUI attempt. If pregnancy does not occur
within the first three cycles, further IUI cycles should not be
performed. IVF for male factor is a further possible option,
with a success rate depending mainly on the woman’s age
(see Table 6). Gamete intrafallopian transfer and zygote in-
trafallopian transfer have been reported to be more effective
than IVF, but are less used techniques because tubal transfer
of the gametes (or the embryo) requires a laparoscopic pro-
cedure. In couples in which IVF of oocytes does not occur and
in patients with severe oligozoospermia and/or severe tera-
tozoospermia or asthenozoopermia, ICSI can be an effective
approach. ICSI has been successfully used in obstructive
azoospermia with spermatozoa obtained by epididymal mi-
crosurgery (microsurgical epididymal sperm aspiration) or
percutaneous aspiration (percutaneous epididymal sperm
aspiration). ICSI can be also performed with success with
testicular spermatozoa obtained by multiple (fine) needle
aspiration (testicular sperm aspiration) or extensive open
testicular biopsies (testicular sperm extraction) in 50–70% of
men with azoospermia due to testicular damage, reduced
testicular volume, and high FSH levels. The implantation
rates obtained with ICSI performed with ejaculated, epidid-
ymal, and testicular spermatozoa are substantially compa-
rable to the results of standard IVF treatments in infertile
couples with pure female factor and unexplained infertility
(33). The multiple, very complex aspects of ICSI for male
factor infertility have been recently reviewed (33).
Flow charts of step-by-step diagnostic assessment and
therapeutic options in the oligoasthenozoospermic and
azoospermic (or severely oligozoospermic) male are re-
ported in Fig. 2, A and B, respectively.
Unexplained infertility
When routine infertility workup yields normal results in
both partners, the couple is defined as suffering from unex-
plained infertility. However, the extent of the routine infer-
tility workup has never been established thoroughly. A basic
protocol must include history and physical examination of
both partners, hormonal profile including midluteal proges-
terone estimation in the woman and semen analysis in the
man. If no abnormalities are found, PCT, HSG, and/or lapa-
roscopy can be considered second-level tests. Nevertheless,
as reported above, additional techniques are available to
further the infertility investigation: bacteriological, immu-
nological screening, genetic assessment, and sperm function
tests. A deep understanding of sperm biology/biochemistry
and the molecular mechanisms of sperm-egg interaction can
lead to a more accurate identification of oocyte/sperm anom-
alies responsible for impaired fertilizing capacity in couples
presenting unexplained infertility (34, 35).
More than 30% of couples with unexplained infertility will
become pregnant within 3 yr of expectant management (30).
However, in case of long-standing, unexplained infertility,
with a female partner more than 30 yr of age it is difficult to
apply this approach. The most effective treatment seems to
be superovulation combined with one ART (IUI, IVF) giving
nearly 2 times higher pregnancy rate compared with that
obtained by superovulation alone (36).
Role of the Endocrinologist in the Management of
the Infertile Couple
According to these guidelines, it is rather evident that the
general endocrinologist can easily perform a first-line diag-
nostic evaluation of the infertile couple as the hormonal
assessment has an important role in the initial workup of
both partners, and semen analysis can be easily interpreted.
It is also rather obvious that if the infertility has an endocrine
cause (e.g. hypogonadotropic hypogonadism, PCOS, or hy-
perprolactinaemia) the endocrinologist has an important role
in the treatment. On the other hand, further diagnostic
workup of the couple requires appropriate knowledge of the
physiology and pathology of the male and female reproduc-
tive tract as well as of second- and third-level diagnostic
procedures. Such experience can be acquired only by endo-
crinologists who want to focus their activity in the area of
reproduction.
TABLE 6. The table summarizes the outcome of all IVF procedures performed in the United States and Canada in 1994
Category No. of IVF cycles with retrieval No. of deliveries % Deliveries for retrieval
Women ,40 yr with no male factor 14,990 3671 24.5%
Women $40 yr with no male factor 2709 243 9.0%
Women ,40 yr with male factor 4485 908 20.2%
Women $40 yr with male factor 866 119 8.5%
The negative effect of female age and male factor diagnosis (when the woman’s age is ,40 yr) is evident (Adapated from Ref. 40).
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A flowchart showing the sequential steps of the diagnostic
assessment and the therapeutic options in couple infertility
is shown in Fig. 1.
Summary and Conclusion
Infertility by itself does not threaten physical health but
has a strong impact on the psychological and social well-
being of couples. In the last two decades, progress in caring
for the infertile couple, in particular progress in the field of
assisted reproduction and micromanipulation, has provided
significant hope for many couples for whom hope could not
have been offered in the past. This is especially true for
bilateral tubal disease and for male factor infertility, as nearly
all couples with male factor infertility can now undergo
either one (or more) IVF or ICSI attempt(s). For couples with
other causes of infertility, however, the differences in preg-
nancy rates often do not reach statistical significance (37). We
must also remember that the total cost incurred for successful
delivery for couples with a better chance of successful IVF
(i.e. those with tubal disease) increases from approximately
$55,000 in American dollars for the first cycle to $73,000 by
the sixth cycle (38). Because of these high costs, many in-
surers in the United States and many public health systems
in Europe do not cover or only partially cover these proce-
dures. Consequently, the availability of IVF and related ther-
apies frequently depends on the couple’s ability to pay.
Therefore, after having established the correct diagnosis, ap-
propriate treatment should be counseled to the infertile cou-
ple keeping in mind the following points: 1) in subfertile
couples expectant management should be reasonably coun-
selled if the age of the woman is less than 30 yr and the
duration of infertility is less than 36 months, even if oligo-
zoospermia is present (30) (Fig. 3); 2) superovulation and
timed intercourse seems also to be a reasonable approach in
couples with anovulatory, mild/moderate endometriosis,
and unexplained infertility (30, 39); 3) in unexplained infer-
tility, ovarian stimulation (with clomiphene or gonadotro-
pin) and IUI seem to offer some advantage over ovarian
stimulation and timed intercourse (1); 4) IVF can be a first-
line approach in tubal sterility and when IUI or IPI cannot be
performed because the number of motile sperm is insuffi-
cient, but is usually also the final treatment attempt when
other methods have failed. The outcome of IVF is negatively
influenced mainly by the woman’s age; however, the number
of deliveries is also generally lower in couples with male
factor (40) (Table 6); 5) ICSI is a further option, which should
be limited to couples: a) with very poor semen parameters;
b) previous failed fertilization; c) presence of obstructive or
nonobstructive azoospermia in which ICSI is combined with
sperm extraction from the epididymis or the testis; 6) inter-
national register studies demonstrate that the risk of mal-
formation after conventional IVF is not increased (41); 7)
some reports suggest that incidence of congenital major and
minor malformations is not increased in children born after
ICSI (42). However, the rate of sex chromosome anomalies in
ICSI fetuses has been reported to be approximately 1% in 585
prenatal diagnoses (43), a frequency increased by a factor of
4 if compared with naturally conceived live-born babies. ICSI
bypasses the physiological selection of spermatozoa that oc-
curs at the level of the testis and epididymis, and in the
female reproductive tract as well as at the sperm-oocyte
interface. As genetic abnormalities are present in a significant
percentage of infertile males with impaired spermatogenesis,
karyotyping and analysis of the Y chromosome for microde-
letions should be carried out in all potential ICSI fathers.
Screening for cystic fibrosis gene mutations should also be
performed in azoospermia caused by congenital absence of
the vas deferens and seminal vesicles. Appropriate genetic
counseling should be made available to all ICSI couples
whenever a gene or chromosomal anomaly has been
identified.
With most ARTs the average delivery rate per cycle is
approximately 15% and the cumulative delivery rate after
several cycles is about 50%. In other words, ARTs, up to now,
can reach approximately 50% of positive results in terms of
live births in couples who decide to assume the direct and
indirect costs of these procedures and their emotional and
social burden. Further research is therefore needed in the
next years to improve the effectiveness of ARTs, on one hand,
and to reduce the need of ARTs on the other. In particular,
as embryo implantation rate after ARTs is considerably lower
than that of natural conceptions, and effective medical treat-
ment is possible only in a small fraction of infertile males,
research should be focused on: 1) elucidation of factors in-
fluencing embryonic implantation; 2) identification of regu-
latory mechanisms of spermatogenesis, spermiation, and ep-
ididymal function; 3) identification of sperm receptors that
react with oocyte ligands and of the signaling cascades that
lead to sperm activation (acrosome reaction, hyperactivated
motility); 4) examination of sperm factors involved in oocyte
activation and molecules that mediate sperm-egg interaction
after penetration and their relationship with early embryo
development.
FIG. 3. Cumulative rate of conceptions leading to live birth in 873
untreated couples with infertility of more than 1 yr in duration.
Cumulative rate at 36 months was 38.2%. The observed conception
rates at 36 months were 33.3, 29.2, 22.6, 20.5, and 20.0% for unex-
plained infertility, oligozoospermia, ovulation defects, minor tubal
defects, and mild endometriosis, respectively [Adapted from Ref. 30,
Fig. 1].
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